Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 USD | +5.00% | -1.41% | -43.05% |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
May. 16 | Craig Hallum Adjusts Inotiv Price Target to $10 From $25, Maintains Buy Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.05% | 51.94M | D+ | ||
+50.76% | 63.85B | B- | ||
-2.21% | 41.83B | B | ||
+40.01% | 40.47B | A | ||
-10.22% | 27.17B | C | ||
+13.66% | 26.52B | B- | ||
-21.65% | 18.69B | B | ||
+3.17% | 12.73B | B+ | ||
+22.07% | 12.11B | B+ | ||
+27.97% | 12.07B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOTV Stock
- Ratings Inotiv, Inc.